加拿大Medicago  
公司是基于植物技术的组合式人体疫苗研发先锋。面对流行性传染病和季节性传染病疫苗供求的挑战，公司成功研制出自有知识产权的瞬变表达系统，该系统使用来自于非转基因植物叶片中的抗原。 公司位于加拿大魁北克市，拥有1300平方米的领军设施，包括高科技温室及下游研发设备。 公司提供多种优于传统蛋基技术及细胞培植技术的强势：速度（3个月内即产出数百万剂），单支剂量的生产成本，以及极低的投资。 目前的产品包括疫苗抗体组合：HA和 NA流感抗体，以及大面积传染性疾病疫苗。

 Medicago is developing highly effective and affordable vaccines based on two proprietary technologies: its plant-based Proficia™ manufacturing technology and its Virus-Like Particles (VLPs). Proficia™ is a robust vaccine and antibody production system based on protein expression in plant leaves. This technology has the potential to offer speed and cost advantages over traditional egg-based and cell production systems. It can deliver a vaccine for testing in less than a month after the identification and reception of genetic sequences from a pandemic strain. Medicago’s VLPs resemble a virus, allowing them to be recognized readily by the immune system however they lack the core genetic material, making them non-infectious and unable to replicate. The Company is currently using tobacco leaves to produce pandemic and seasonal influenza VLP vaccines.